Abstract：
BACKGROUND: Adjuvant chemotherapy improves the prognosis of patients with colorectal cancer (CRC) following radical resection. However, the safety and efficacy of oxaliplatin-based chemotherapeutic regimens for elderly patients remains to be elucidated. The aim of the present study was to examine the tolerability and efficacy of adjuvant CAPOX (capecitabine and oxaliplatin) therapy for elderly patients in comparison with young patients.
METHODS: We examined 138 Japanese patients who received adjuvant CAPOX therapy for high-risk stage II or III CRC between July 2010 and June 2021 at our hospital. Patients were divided according to an age of 70 years. Treatment details of CAPOX therapy were analyzed in association with age. Moreover, prognosis of stage III CRC was compared between the patient groups.
RESULTS: Twenty-three patients (17%) were ≥70 years old. Male patients were predominant in the ≥70 years group (p = 0.006). Patients ≥70 years old had more comorbidities (diabetes, p = 0.014; cardiovascular disease, p < 0.001; renal disease, p = 0.042) than patients <70 years old. There were no age-dependent differences in dose intensity, the number of cycles, or DLTs of CAPOX therapy. CSS and RFS were also similar between the ≥70 and <70 years old patients with stage III CRC.
CONCLUSIONS: Adjuvant CAPOX therapy was tolerable in elderly Japanese patients. The prognosis of elderly patients with stage III CRC was similar to that of their younger counterparts. Advanced age itself may not be a contraindication for adjuvant chemotherapy in CRC. Future studies with a larger patient cohort are required to confirm the present results.
METHODS: We examined 138 Japanese patients who received adjuvant CAPOX therapy for high-risk stage II or III CRC between July 2010 and June 2021 at our hospital. Patients were divided according to an age of 70 years. Treatment details of CAPOX therapy were analyzed in association with age. Moreover, prognosis of stage III CRC was compared between the patient groups.
RESULTS: Twenty-three patients (17%) were ≥70 years old. Male patients were predominant in the ≥70 years group (p = 0.006). Patients ≥70 years old had more comorbidities (diabetes, p = 0.014; cardiovascular disease, p < 0.001; renal disease, p = 0.042) than patients <70 years old. There were no age-dependent differences in dose intensity, the number of cycles, or DLTs of CAPOX therapy. CSS and RFS were also similar between the ≥70 and <70 years old patients with stage III CRC.
CONCLUSIONS: Adjuvant CAPOX therapy was tolerable in elderly Japanese patients. The prognosis of elderly patients with stage III CRC was similar to that of their younger counterparts. Advanced age itself may not be a contraindication for adjuvant chemotherapy in CRC. Future studies with a larger patient cohort are required to confirm the present results.
摘要：
背景：辅助化疗可改善结直肠癌（CRC）患者根治性切除术后的预后。然而,基于奥沙利铂的化疗方案对老年患者的安全性和有效性尚待阐明.本研究的目的是研究辅助CAPOX（卡培他滨和奥沙利铂）治疗老年患者与年轻患者的耐受性和疗效。
方法：我们检查了2010年7月至2021年6月期间在我院接受CAPOX辅助治疗高危II期或III期CRC的138例日本患者。患者根据70岁的年龄进行划分。分析CAPOX治疗的治疗细节与年龄相关。此外，在患者组之间比较了III期CRC的预后.
结果：23例（17%）患者年龄≥70岁。≥70岁组中男性患者占优势（p=0.006）。≥70岁的患者有更多的合并症(糖尿病，p=0.014;心血管疾病，p<0.001；肾病，p=0.042)比<70岁的患者。剂量强度没有年龄依赖性差异，循环次数,或CAPOX治疗的DLT。≥70岁和<70岁的III期CRC患者的CSS和RFS也相似。
结论：在日本老年患者中，辅助CAPOX治疗是可以耐受的。老年III期CRC患者的预后与年轻患者相似。高龄本身可能不是CRC辅助化疗的禁忌症。未来需要更大的患者队列研究来确认目前的结果。
方法：我们检查了2010年7月至2021年6月期间在我院接受CAPOX辅助治疗高危II期或III期CRC的138例日本患者。患者根据70岁的年龄进行划分。分析CAPOX治疗的治疗细节与年龄相关。此外，在患者组之间比较了III期CRC的预后.
结果：23例（17%）患者年龄≥70岁。≥70岁组中男性患者占优势（p=0.006）。≥70岁的患者有更多的合并症(糖尿病，p=0.014;心血管疾病，p<0.001；肾病，p=0.042)比<70岁的患者。剂量强度没有年龄依赖性差异，循环次数,或CAPOX治疗的DLT。≥70岁和<70岁的III期CRC患者的CSS和RFS也相似。
结论：在日本老年患者中，辅助CAPOX治疗是可以耐受的。老年III期CRC患者的预后与年轻患者相似。高龄本身可能不是CRC辅助化疗的禁忌症。未来需要更大的患者队列研究来确认目前的结果。
